[A comparative clinical and pathological study on the classification and prognostic features of 57 thymomas. II. prognostic features (author's transl)].

H F Otto
{"title":"[A comparative clinical and pathological study on the classification and prognostic features of 57 thymomas. II. prognostic features (author's transl)].","authors":"H F Otto","doi":"10.1007/BF00305976","DOIUrl":null,"url":null,"abstract":"<p><p>The most important prognostic determinants of the thymomas are the gross findings at operation (equal to the presence or absence of gross invasion of adjacent tissue) and the presence or absence of the thymoma-associated systemic disease, particulary myasthenia gravis. The histologic type of thymoma had no proof value in predicting prognosis with the exception of the so-called atypical thymomas. Thirty-four of 57 patients with thymomas were females and 23 males. The tumors in 40 cases were non-invasive thymomas, and in 17 cases the tumour were invasive of adjacent tissue. 35.1 percent of patients were asymptomatic, the tumours being discovered on roentgenograms done on a routine basis or for an unrelated porpose. 40.3 percent of patients have had a thymoma-associated systemic disease. The most common presenting symptoms were related to myasthenia gravis (26.3%). The 5-year survival rate was 90 percent for non-invasive thymomas without myastenia gravis and 50 percent for invasive thymomas. The 5-year survival rate for patients with myasthenia gravis and encapsulated (non-invasive) thymomas was approximately 60 percent, whereas that for invasive thymomas with myasthenia gravis was 40 percent. The primary form of therapy for all thymomas is the surgical excision. In cases with invasive and/or metastasizing thymomas, postoperative radiation and adjuvanted chemotherapy is indicated, but in most series, the longterm results of this form of therapy are discouraging.</p>","PeriodicalId":76850,"journal":{"name":"Zeitschrift fur Krebsforschung und klinische Onkologie. Cancer research and clinical oncology","volume":"91 1","pages":"103-15"},"PeriodicalIF":0.0000,"publicationDate":"1978-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF00305976","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zeitschrift fur Krebsforschung und klinische Onkologie. Cancer research and clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/BF00305976","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

The most important prognostic determinants of the thymomas are the gross findings at operation (equal to the presence or absence of gross invasion of adjacent tissue) and the presence or absence of the thymoma-associated systemic disease, particulary myasthenia gravis. The histologic type of thymoma had no proof value in predicting prognosis with the exception of the so-called atypical thymomas. Thirty-four of 57 patients with thymomas were females and 23 males. The tumors in 40 cases were non-invasive thymomas, and in 17 cases the tumour were invasive of adjacent tissue. 35.1 percent of patients were asymptomatic, the tumours being discovered on roentgenograms done on a routine basis or for an unrelated porpose. 40.3 percent of patients have had a thymoma-associated systemic disease. The most common presenting symptoms were related to myasthenia gravis (26.3%). The 5-year survival rate was 90 percent for non-invasive thymomas without myastenia gravis and 50 percent for invasive thymomas. The 5-year survival rate for patients with myasthenia gravis and encapsulated (non-invasive) thymomas was approximately 60 percent, whereas that for invasive thymomas with myasthenia gravis was 40 percent. The primary form of therapy for all thymomas is the surgical excision. In cases with invasive and/or metastasizing thymomas, postoperative radiation and adjuvanted chemotherapy is indicated, but in most series, the longterm results of this form of therapy are discouraging.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
57例胸腺瘤分型及预后的临床病理比较研究。2预后特征(作者译)]。
胸腺瘤最重要的预后决定因素是手术时的大体表现(等于有无邻近组织的大体侵犯)和胸腺瘤相关的全身性疾病,特别是重症肌无力的存在或不存在。除了所谓的非典型胸腺瘤外,胸腺瘤的组织学类型在预测预后方面没有证据价值。57例胸腺瘤患者中34例为女性,23例为男性。40例肿瘤为非侵袭性胸腺瘤,17例肿瘤为浸润性邻近组织。35.1%的患者无症状,肿瘤是在常规或无关目的的x线照片上发现的。40.3%的患者患有胸腺瘤相关的全身性疾病。最常见的症状与重症肌无力有关(26.3%)。无重症肌无力的非侵袭性胸腺瘤的5年生存率为90%,侵袭性胸腺瘤的5年生存率为50%。重症肌无力合并包被性胸腺瘤患者的5年生存率约为60%,而侵袭性胸腺瘤合并重症肌无力患者的5年生存率为40%。所有胸腺瘤的主要治疗形式是手术切除。在侵袭性和/或转移性胸腺瘤的病例中,术后放疗和辅助化疗是指的,但在大多数系列中,这种形式的治疗的长期结果令人沮丧。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Effect of generalized graft-versus-host-reaction on B- and T-lymphocytes and a benzpyrene-induced murine sarcoma. Bleomycin: effect on satellite DNA in mouse fibroblasts. The fine structure of monoclonal Hodgkin cells cultured in diffusion chambers. Effect of splenectomy on B- and T-lymphocytes and a benzpyrene-induced murine sarcoma. Release of glycolytic enzymes from cultivated tumor cells.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1